Literature DB >> 35837166

Abrogation of ARF6 in promoting erastin-induced ferroptosis and mitigating capecitabine resistance in gastric cancer cells.

Donghua Geng1, Huiying Wu2.   

Abstract

Background: ADP ribosylation factor 6 (ARF6) is a member of the Rat sarcoma virus (RAS) superfamily that is involved in the regulation of vesicular trafficking, membrane lipid remodeling, and signaling pathways. Our earlier work discovered that ARF6, as a downstream effector of the Kirsten rat sarcoma viral oncogene (Kras)/extracellular signal-regulated kinases (ERK) signaling pathway, may increase proliferation and induce the Warburg effect in gastric cancer (GC) cells. Additionally, ARF6 appears to be a potential biomarker for predicting the prognosis of GC. Ferroptosis has recently been described as a type of nonapoptotic iron-dependent cell death that is strongly associated with the Kras mutation. Therefore, it is critical to continue investigating the link between ARF6 and ferroptosis.
Methods: We first created ARF6 silenced cancer cell lines with lentivirus transfection. The knockdown efficiency was confirmed through quantitative polymerase chain reaction (qPCR) and western blotting. Subsequently, we used Cell Counting Kit-8 (CCK-8) and malondialdehyde (MDA) assay for lipid peroxidation measurement. Following this, qPCR and western blotting were conducted to clarify the mechanism involved. Finally, immunohistochemistry was used to stain human GC samples.
Results: Our findings established that, whereas ARF6 did not directly regulate lipid peroxidation, it did render GC cells susceptible to oxidative stress, particularly erastin-induced lipid peroxidation. Additionally, our research demonstrated that ARF6 may control capecitabine resistance via several routes. Conclusions: ARF6 may play a critical role in the development of GC. 2022 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  ADP ribosylation factor 6 (ARF6); Ferroptosis; capecitabine; erastin; gastric cancer (GC)

Year:  2022        PMID: 35837166      PMCID: PMC9274056          DOI: 10.21037/jgo-22-341

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  32 in total

Review 1.  KRAS Alleles: The Devil Is in the Detail.

Authors:  Kevin M Haigis
Journal:  Trends Cancer       Date:  2017-09-12

2.  Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.

Authors:  Jong-Lyel Roh; Eun Hye Kim; Hye Jin Jang; Jin Young Park; Daiha Shin
Journal:  Cancer Lett       Date:  2016-07-28       Impact factor: 8.679

3.  Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice.

Authors:  Jose Pedro Friedmann Angeli; Manuela Schneider; Bettina Proneth; Yulia Y Tyurina; Vladimir A Tyurin; Victoria J Hammond; Nadja Herbach; Michaela Aichler; Axel Walch; Elke Eggenhofer; Devaraj Basavarajappa; Olof Rådmark; Sho Kobayashi; Tobias Seibt; Heike Beck; Frauke Neff; Irene Esposito; Rüdiger Wanke; Heidi Förster; Olena Yefremova; Marc Heinrichmeyer; Georg W Bornkamm; Edward K Geissler; Stephen B Thomas; Brent R Stockwell; Valerie B O'Donnell; Valerian E Kagan; Joel A Schick; Marcus Conrad
Journal:  Nat Cell Biol       Date:  2014-11-17       Impact factor: 28.824

Review 4.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

Authors:  Dominico Vigil; Jacqueline Cherfils; Kent L Rossman; Channing J Der
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

5.  Regulation of ferroptotic cancer cell death by GPX4.

Authors:  Wan Seok Yang; Rohitha SriRamaratnam; Matthew E Welsch; Kenichi Shimada; Rachid Skouta; Vasanthi S Viswanathan; Jaime H Cheah; Paul A Clemons; Alykhan F Shamji; Clary B Clish; Lewis M Brown; Albert W Girotti; Virginia W Cornish; Stuart L Schreiber; Brent R Stockwell
Journal:  Cell       Date:  2014-01-16       Impact factor: 41.582

6.  Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.

Authors:  Zhengle Zhang; Qingke Duan; Hengqiang Zhao; Tao Liu; Heshui Wu; Qiang Shen; Chunyou Wang; Tao Yin
Journal:  Cancer Lett       Date:  2016-08-26       Impact factor: 8.679

7.  The modification of ferroptosis and abnormal lipometabolism through overexpression and knockdown of potential prognostic biomarker perilipin2 in gastric carcinoma.

Authors:  Xiaoying Sun; Shaojuan Yang; Xuechao Feng; Yaowu Zheng; Jinsong Zhou; Hai Wang; Yucheng Zhang; Hongyan Sun; Chengyan He
Journal:  Gastric Cancer       Date:  2019-09-13       Impact factor: 7.370

8.  Loss of cysteinyl-tRNA synthetase (CARS) induces the transsulfuration pathway and inhibits ferroptosis induced by cystine deprivation.

Authors:  M Hayano; W S Yang; C K Corn; N C Pagano; B R Stockwell
Journal:  Cell Death Differ       Date:  2015-07-17       Impact factor: 15.828

Review 9.  Genetic Profiles of Ferroptosis in Malignant Brain Tumors and Off-Target Effects of Ferroptosis Induction.

Authors:  Marc Dahlmanns; Eduard Yakubov; Jana Katharina Dahlmanns
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

10.  Vulnerability of Triple-Negative Breast Cancer to Saponin Formosanin C-Induced Ferroptosis.

Authors:  Hsin-Chih Chen; Han-Hsuan Tang; Wei-Hsiang Hsu; Shan-Ying Wu; Wen-Hsing Cheng; Bao-Yuan Wang; Chun-Li Su
Journal:  Antioxidants (Basel)       Date:  2022-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.